Skip to main content

Table 2 Current pharmaceutical disease-modifying clinical trials phase II and III

From: Novel targeted therapies for Parkinson’s disease

Τargeting mechanism ClinTrial indentifier Drug Phase Τarget population Primary outcome Other secondary outcomes of interest Sponsor
A2Α receptor antagonists NCT03703570 KW-6356 II PD Changes in MDS-UPDRS part III . Kyowa Kirin Co., Ltd.
  NCT02939391 KW-6356 II Early PD Changes in MDS-UPDRS part III . Kyowa Kirin Co., Ltd.
Calcium Targeting Therapies NCT02168842 Isradipine III Early PD Changes in MDS UPDRS Part I-III . University of Rochester
Glucagon-like peptide 1 receptor agonists and other antidiabetic agents NCT03659682 Semaglutide II Early PD Changes in MDS-UPDRS part 3 in OFF medication state . Oslo University Hospital
  NCT02953665 Liraglutide II Early PD Motor Function, Non-Motor Function, Cognitive Function . Cedars-Sinai Medical Center
  NCT03439943 Lixisenatide II Early PD Changes in MDS-UPDRS Part III in ON status . University Hospital, Toulouse
  NCT04305002 Εxenatide II Early PD Changes in FDG-PET network analysis Changes in MDS-UPDRS Part III in ON and OFF status Center for Neurology, Stockholm
Karolinska Institutet
  NCT04154072 NLY01 ΙΙ Early Treatment Naïve PD Changes in MDS UPDRS Part II-III . Neuraly, Inc
  NCT04232969 Εxenatide III PD Changes in MDS-UPDRS part III in OFF medication state . University College, London
  NCT04269642 Εxenatide II Early PD Changes in MDS-UPDRS part III score Changes in SNBR confirmed by PET scan Peptron, Inc.
Glucocerebrosidase targeting therapies NCT02914366 Αmbroxol II PD Dementia Changes in ADAS-cog and
ADCS-CGIC scales
Changes in MRI biomarkers Lawson Health Research Institute
  NCT02906020 GZ/SAR402671 II Patients with Early PD Carrying a GBA Gene Mutation Number of Patients with AE, Changes in UPDRS Part II and III during OFF state . Genzyme, a Sanofi Company
  NCT04127578 PR001A I/II Patients with PD With at Least One GBA1 Mutation Number of TEAEs and SAEs . Prevail Therapeutics
Targeting α-synuclein:
Immunotherapies
NCT03100149 RO7046015/
PRX002
II Early PD Changes in MDS-UPDRS total score Changes in DaT-SPECT Hoffmann-La Roche
  NCT03318523 BIIB054 II PD Changes in MDS-UPDRS total score Change in SBR measured by SPECT/DATSCAN Biogen
Targeting α-synuclein:
prevention of aggregation
NCT03655236 K0706 II Early PD Changes in MDS UPDRS Part II-III Changes in DaT-SPECT Sun Pharma Advanced Research Company Limited
Ιron Targeting Therapies NCT02655315 Deferiprone II Treatment Naive PD Changes in total MDS-UPDRS . University Hospital, Lille European Commission ApoPharma
  1. ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, ADCS-CGIS ADCS-Clinician’s Global Impression of Change, AE Adverse Events, DATSCAN Dopamine Transporter With Ioflupane I123, FDG-PET Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose, MDS-UPDRS Unified Parkinson’s Disease Rating Scale, MRI Magnetic Resonance Imaging, PD Parkinson’s Disease, PET positron emission tomography, SAEs Serious Adverse Events, SNBR specific to non-specific binding ratio, SBR Striatal Binding Ratio, SPECT Single Photon Emission Computed Tomography, TEAEs Treatment-Emergent Adverse Event